Ehsan Nazemalhosseini Mojarad 1, 2, Mohammad Rostami Nejad1,
Ali Haghighi2
1 Research Center for Gastroenterology and Liver Diseases,
Shahid Beheshti University M.C.,
2
Department of Medical Parasitology & Mycology,
School
of Medicine, Shahid Beheshti University M.C., Tehran, Iran
ABSTRACT
Amebiasis is the infection of the human gastrointestinal tract by
Entamoeba histolytica, a protozoan parasite that is capable of invading the
intestinal mucosa and may spread to other organs, mainly the liver. The
detection of Entamoeba histolytica from the nonpathogenic but identically
appearing parasites Entamoeba dispar and Entamoeba moshkovskii is an
important goal of the clinical microbiology laboratory. Currently, there is
no low-cost laboratory test available for the differentiation of
E. histolytica from E. dispar infections. It is likely that at least 90% of
the infections previously ascribed to E. histolytica are actually E. dispar,
while only the remaining 10% are infected with E. histolytica in its new
sense. The present manuscript review recent advances in this regard. The
purpose of this study is to alert physicians (and perhaps with their help,
laboratories) to the importance of distinguishing between the two species of
amoebae.
Keywords: Amebiasis, Entamoeba histolytica, Entamoeba dispar,
Entamoeba moshkovskii.
(Gastroenterology and Hepatology
from bed to bench 2008;1(1):45-50).
INTRODUCTION
PATHOLOGY and CLINICAL MANAGEMENT
Amebiasis is the infection of the human
gastrointestinal tract by Entamoeba histolytica, a protozoan parasite that is
capable of invading the intestinal mucosa and may spread to other organs, mainly
the liver. Entamoeba dispar, an ameba morphologically similar to E. histolytica
that also colonizes the human gut, has been recognized recently as a separate
species with no invasive potential (2,5,13,14). Depending on the affected organ,
the clinical manifestations of amebiasis are intestinal or extraintestinal.
There are four clinical forms of invasive intestinal amebiasis, all of which are
generally acute: dysentery or bloody diarrhea, fulminating colitis, amebic
appendicitis, and ameboma of the colon. Dysenteric and diarrheic syndromes
account for 90% of cases of invasive intestinal amebiasis. Patients with
dysentery have an average of three to five mucosanguineous evacuations per day,
with moderate colic pain preceding discharge, and they have rectal tenesmus. In
patients with bloody diarrhea, evacuations are also few but the stools are
composed of liquid fecal material stained with blood. While there is moderate
colic pain, there is no rectal tenesmus. Fever and systemic manifestations are
generally absent. These syndromes constitute the classic ambulatory dysentery
and can easily be distinguished from that of bacterial origin, where the patient
frequently complains of systemic signs and symptoms such as fever, chills,
headache, malaise, anorexia, nausea, vomiting, cramping abdominal pain, and
tenesmus (15).
Although E. histolytica can infect almost every organ
of the body, the most frequent form of extraintestinal amebiasis is the amebic
liver abscess. This condition, which results from the migration of trophozoites
from the colon to the liver through the portal circulation, is more common in
adults than in children and more frequent in males than in females for 10 and
3 times respectively (16,17). In general, the onset is abrupt, with pain in the
right hypochondrium radiating toward the right shoulder and scapular area. The
pain usually increases with deep breathing, with coughing, and while stepping on
the right foot during walking. When the abscess is localized to the right lobe,
symptoms include an irritative cough that is sometimes productive and a
pleuritic type of chest pain. Abscesses in the upper left lobe can cause
epigastric, sometimes dyspneic pain, at times spreading to the base of the neck
and to one or both shoulders. Fever between 38 to 40°C is found in 85 to 90% of
patients with amebic liver abscess. The patient commonly has chills and profuse
sweating in the afternoon and at night. Other symptoms include anorexia, nausea,
vomiting, diarrhea (with or without blood), and dysentery.
On physical examination, the cardinal sign of amebic
liver abscess is painful hepatomegaly. Digital pressure and fist percussion will
often produce intense pain in the liver region. On palpation, the liver is soft
and smooth, in contrast to the rough, hard, irregular character of the liver in
patients with cirrhosis and hepatocarcinoma. Jaundice is present in 8% of the
patients who respond well to treatment. When jaundice is severe, multiple
abscesses should be suspected. Diarrhea or dysentery is seen in less than
one-third of patients. Complications of amebic liver abscess include perforation
to the pericardial space, pleura, or peritoneal cavity (15,17).
The diagnosis of invasive intestinal amebiasis is still
based on the microscopic identification of E. histolytica trophozoites in rectal
smears or recently evacuated stools and on the results of rectosigmoidoscopy.
Trophozoites are most likely to be found in the bloody mucus and in the
yellowish exudates covering the mucosal ulcerations obtained during
rectosigmoidoscopy. Diagnostic problems arise when only cysts are identified in
stools of healthy or diarrheic individuals. A commercially available laboratory
test based on the identification of specific E. histolytica antigens in stool
(3) is able to discriminate E. histolytica from E. dispar cysts (W. A. Petri,
unpublished observations). However, the high cost and lack of knowledge of this
test have hindered its use in clinical laboratories, especially in countries
where amebiasis is endemic. Until these new diagnostic tests are widely
available to clinical laboratories, these samples should be reported as
containing E. histolytica/E. dispar (2,17).
DIAGNOSIS
How should physicians respond to a laboratory diagnosis
of Amebiasis? First, they need to know whether the laboratory reporting E.
histolytica has identified the pathogenic organism, an event which seldom occurs
at present. Perhaps at the urging of physicians, more and more laboratories will
recognize the importance of distinguishing between the two species. If a
laboratory does not yet differentiate pathogenic from nonpathogenic species,
then any reported E. histolytica should be treated, even in asymptomatic
patients, because symptoms may appear in that person later and because the
patient may carry infection to others. In this regard, clinical judgment should
be modified by the realization that the pathogen is considerably rarer than
previously believed (1,2,13). The World Health Organization has recommended that
Entamoeba histolytica "should be specifically identified and if present should
be treated" (1). The diagnosis of amebic liver abscess is sometimes difficult
(1). In areas of endemic infection or when there is a history of travel to such
places, amebic abscess should be suspected in patients with spiking fever,
weight loss, and abdominal pain in the upper right quadrant or epigastrium and
in patients with tenderness in the liver area. The presence of leukocytosis, a
high alkaline phosphatase level, and an elevated right diaphragm suggest a
hepatic abscess. The diagnosis is confirmed by ultrasonography or by computed
tomography (CT) scans. The CT scan is the most precise method for identifying
hepatic abscesses, especially when they are small, and following intravenous
injection of contrasting agents, it is of great value in the differential
diagnosis of other focal lesions of the liver (16). Serological tests for
antiamebic antibodies are positive in approximately 75% of patients with
invasive colonic amebiasis and in over 90% of patients with amebic liver
abscesses. Most studies have focused on a single factor in an attempt to dissect
the multiple mechanisms used by the parasite that ultimately result in tissue
destruction (17). Some problems exist to distinguish between IBD and colitis
associated with amoeba according to both symptomatic and endoscopic appearance
of the colon. Sometimes IBD can co-exist with amebiasis. This, of course, leads
to confusion in the diagnosis and treatment of the disease (4).
Preliminary data obtained from the application of these methods confirm the
presence of E. dispar in most asymptomatic amebic infections, although E. histolytica
asymptomatic colonization is not uncommon (18).
EPIDEMIOLOGY
Intestinal and extra-intestinal amebiasis remains a
significant health concern worldwide, especially in developing countries.
Asymptomatic cyst passing is the most common manifestation of the intestinal
Entamoeba infection. An estimated 10% of world’s population are infected with E.
histolytica / E. dispar, and between 40,000 to 110,000 individuals die of
invasive amebiasis annually (1,2). It has been known that many people who are
apparently infected with E. histolytica never develop symptoms and then
infections clear spontaneously (19,20). In previous study on amebiasis in
The realization that Entamoeba histolytica and
Entamoeba dispar are two distinct but morphologically identical species (5) has
had a major impact on all aspects of amebiasis research, most notably
epidemiology (1,2). It is very important to keep in mind that according
to the older data, many E. histolytica infections were most probably confused
with E. dispar due to limited data obtained from microscopic examinations.
Epidemiological studies have shown that low socioeconomic status and unsanitary
conditions are significant independent risk factors for infection. In addition,
people living in developing countries have a higher risk and earlier age of
infection than do those in developed regions. Invasive amebiasis due to E. histolytica
is more common in developing countries. In areas of endemic infection, a variety
of conditions including ignorance, poverty, overcrowding, inadequate and
contaminated water supplies, and poor sanitation favor direct fecal-oral
transmission of amebas from one person to another. It is now known that even in
areas where invasive amebiasis is common, E. dispar is by far the most prevalent
species (26).
DIVERSITY AMONG ISOLATES
Since the first description of amebiasis in 1878 by
Lo¨sch (27), we still do not have a proper answer to the question of why disease
and symptoms develop in only 5 to 10% of those infected with E. histolytica. It
has been speculated that a spectrum of virulence levels among the E. histolytica
strains and variability in the host immune response against amebic invasion
contribute to the outcome of amebic infection. While variation in human immune
responses against amebic infection is not understood, the polymorphic structure
of E. histolytica has recently been unveiled (28), but is E. dispar really
nonpathogenic, and should it on this basis be completely dismissed as a subject
for further investigation? It has been shown to be capable of producing variable
focal intestinal lesions in animals and of destroying epithelial cell monolayers
in vitro. There is also some evidence that pathological changes may occur in
some humans, though, invasive lesions and symptomatic infections have to date
not been reported. Whether these characteristics are variable among strains is
unknown (29). We propose that molecular typing and analysis of genotypes of E.
histolytica isolates from a variety of geographic locations should help in
determining geographic origins of isolates and routes of transmission.
CONCLUSION
The acceptance of Entamoeba histolytica and Entamoeba
dispar as distinct species has had a major impact on our views of amebiasis, in
particular its clinical management and epidemiology. It is likely that at least
90% of the infections previously ascribed to E. histolytica are actually E. dispar,
while only the remaining 10% are infected with E. histolytica in its new sense.
However, it also appears that many E. histolytica infections never progress to
become symptomatic and are spontaneously lost. This observation raises some
important questions. Are the organisms that produce invasive, symptomatic
disease genetically distinct from those that give rise to asymptomatic
infections? Or do all E. histolytica isolates have the potential to become
invasive? Do certain invasive isolates show tropism for specific organs, with
some preferentially ending up in the intestinal wall while others reach
extraintestinal sites? To address the possibility of a relationship between
parasite variation and infection outcome, the ability to differentiate isolates
of E. histolytica is necessary (1,5,8). The World Health Organization has
recommended that Entamoeba histolytica “should be specifically identified and if
present should be treated” (1,2). Until that time, epidemiological data on
amebiasis were mainly based on microscopic detection of E. histolytica/E. dispar
cysts without the differentiation between the two species. Moreover, many cases
will be missed, as the sensitivity of microscopy is known to be low (8). As a
result, accurate data on the prevalence of E. histolytica is not available and
therefore there is a need to obtain such data using specific and more sensitive
tools. When diagnosing a patient who has a medical history and clinical findings
suggestive of infectious enteritis, physicians usually start their investigation
by ordering a stool culture and one or more stool specimens to be examined for
protozoa and other parasites. If the initial culture result is negative and the
laboratory identifies Entamoeba histolytica, treatment for that parasite will
probably be given, and subsequent investigation will be curtailed. However,
recent discoveries suggest that this approach may be incorrect most of the time,
because we now know that what has been considered E. histolytica actually
includes two distinct species, the much more common of which is always
nonpathogenic. The purpose of this short account is to alert physicians (and
perhaps with their help, laboratories) to the importance of distinguishing
between the two species of amoebae.
ACKNOWLEDGEMENT
REFERENCES
1.
WHO/PAHO/UNESCO. A consultation with
experts on amebiasis. Epidemiol Bull 1997;18:13-14.
2.
Anonymous.
Entamoeba taxonomy. WHO Bull 1997;75:291–92.
3.
Haque R, Ali IKM,
Akther S, et al. Comparison of PCR, isoenzyme analysis, and antigen detection
for diagnosis of Entamoeba histolytica infection. J Clin Microbiol
1998;36:449–52.
4.
Garcia LS,
editor. Diagnostic medical parasitology. 4th edition. ASM Press,
Washington, 2001.
5.
Diamond LS,
6.
Gathiram V,
Jackson TF. Frequency distribution of Entamoeba histolytica
zymodemes in a rural South African population. Lancet 1985;719–21.
7.
Gonzalez-Ruiz A,
Haque R, Aguirre A, et al. Value of microscopy in the diagnosis of dysentery
associated with invasive Entamoeba histolytica. J Clin Pathol 1994;47:236–39.
8.
Zaki M, Clark CG.
Isolation and characterization of polymorphic DNA from. Entamoeba histolytica. J
Clin Microbiol 2001;39(3):897-905
9.
Haque R,
10.
Krogstad DJ,
Spencer HC, Healy GR, et al. Amebiasis: epidemiologic studies in the United
States, 1971–1974. Ann Intern Med 1978;88:89–97.
11.
Strachan WD,
12.
Haque R, Mollah
NU, Ali IKM, et al. Diagnosis of amebic liver abscess and intestinal infection
with the TechLab Entamoeba histolytica II antigen detection and antibody
tests. J Clin Microbiol 2000;38:3235–39.
13.
14.
Martinez-Palomo
A, Espinosa-Cantellano M. Amoebiasis: new understanding and new goals. Parasitol
Today 1998;14:1–3.
15.
Martinez-Palomo
A, Espinosa Cantellano M. Intestinal amoebae. In: Cox FEG, Kreier
JP, Wakelin D, editors. Topley & Wilson’s microbiology and microbial infections.
Edward Arnold,
16.
Sepu´lveda B,
Manzo N. Clinical manifestations and diagnosis of amebiasis.
In:
Martinez-Palomo A, editor. Amebiasis.
Elsevier Science Publishing,
17.
Cantellano E,
Palomo M. Pathogenesis of intestinal
amebiasis: from molecules to disease. Clin Microbiol Rev 2000;13(2):318–31.
18.
Braga LL, Lima
AAM, Sears CL, et al. Seroepidemiology of Entamoeba histolytica in a slum
in